Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Reports Success In Anti-Kickback Effort In Drug Sector

This article was originally published in PharmAsia News

Executive Summary

Chinese authorities say kickbacks by drug makers to physicians who prescribe their drugs contributed to illicit revenue that has totaled more than $5.5 million since November 2007. The report by the Communist Party of China Central Commission for Discipline Inspection covers the period since China launched an anti-corruption clampdown. One of the methods it used was to adopt a bidding system for municipalities, provinces and autonomous regions to procure drugs, with 90 percent of prescriptions supplied under that system. The report also cited new regulations on the pricing and registration of drugs as helping to prevent corruption. (Click here for more

You may also be interested in...



Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 

UsernamePublicRestriction

Register

LL1133229

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel